Interestingly, we observed that TNFα treatment decreased the expression levels and the secretion of the cholesterol acceptor APOE, which is the major lipid acceptor in CNS and is the strongest genetic risk factor involved in AD [33,34] (Figure 2A–C). Here, APOE is linked to Alzheimer disease.